Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct 30;72(6):855-872.
doi: 10.1007/s10616-020-00430-7. Online ahead of print.

The comparison of miRNAs that respond to anti-breast cancer drugs and usnic acid for the treatment of breast cancer

Demet Cansaran-Duman  1 , Ümmügülsüm Tanman  2 , Sevcan Yangın  2 , Orhan Atakol  3
Affiliations

The comparison of miRNAs that respond to anti-breast cancer drugs and usnic acid for the treatment of breast cancer

Demet Cansaran-Duman et al. Cytotechnology. .

Abstract

This study was designed to compare usnic acid with anti-breast cancer drug molecules (A-BCDM) routinely used in the treatment of breast cancer. The miRNA information of 17 anti-breast cancer drug used in breast cancer treatment was obtained from the Small Molecule-miRNA Network-Based Inferance (SMIR-NBI) tool. We had been determined common and different expressed miRNAs between 17 A-BCDM & usnic acid and were classified according to the common miRNAs to reveal molecular similarity. As a result of the bioinformatic analyzes, 20 common miRNAs were determined between 17 A-BCDM and usnic acid. The common miRNAs were analyzed with bioinformatic tolls for determining pathways and targets. The most common miRNAs for 6 of 17 A-BCDM and usnic acid were determined as miR-374a-5p and miR-26a-5p. We compared the anti-proliferative effect of usnic acid and one of the 17 A-BCDM that tamoxifen on MDA-MB-231 triple negative breast cancer cell with real-time cell analysis system. The real time PCR assay was carried out with miR-26a-5p for evaluate to expression level of MDA-MB-231 breast cancer cell and MCF-12A non-cancerous epithelial breast cell. As a result of study, usnic acid as novel candidate drug molecule showed high similarity ratio with 5-Fluorouracil, Sulindac Sulfide, Curcumin and Cisplatin A-BCDM used in treatment of breast cancer. miR-26a-5p as common response miRNA of usnic acid and tamoxifen was showed a decreased level of expression by validated qRT-PCR assay. The obtained from study, in addition to 17 A-BCDM, usnic acid has also the potential to be used as a candidate molecule in the treatment of breast cancer. Moreover, miR-26a-5p might be used as a biomarker in the treatment of breast cancer but further analysis is required.

Keywords: Anti-breast cancer drugs; Breast cancer; Usnic acid; miRNA.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
miRNA numbers and similarity rates commonly expressed between usnic acid and 17 anti-breast cancer drugs
Fig. 2
Fig. 2
The similarity relationship between miRNAs responding to the usnic acid and the miRNAs responding to the anti-breast cancer drugs
Fig. 3
Fig. 3
miRNAs of 17 anti-cancer drugs and usnic acid with similar expression levels (*: The common miRNA profiles of 17 anti-cancer drugs and usnic acid
Fig. 4
Fig. 4
The number of target gene of common miRNAs between usnic acid and 17 anti-breast cancer drugs
Fig. 5
Fig. 5
The determination of antiproliferative effect for tamoxifen and usnic acid by XCELLigence assay
Fig. 6
Fig. 6
The expression analyses for miR-26a-5p on MDA-MB-231 and MCF-12A cell lines treated with usnic acid by usnig qRT-PCR assay. (*p < 0.01) (**p < 0.001)
Fig. 7
Fig. 7
Antiproliferative effect of miR-26a-5p on MDA-MB-231 (green = control, red = scramble, blue:miR-26a-5p). Each transfection is quantified in duplicate (p < 0.001). (Color figure online)
See this image and copyright information in PMC

References

    1. Bartel D. MicroRNAs. Cell. 2004;116:281–297. doi: 10.1016/S0092-8674(04)00045-5. - DOI - PubMed
    1. Comprehensive molecular portraits of human breast tumours (2012) Nature 490:61–70 - PMC - PubMed
    1. Creighton C, Nagaraja A, Hanash S, Matzuk M, Gunaratne P. A bioinformatics tool for linking gene expression profiling results with public databases of microRNA target predictions. RNA. 2008;14:2290–2296. - PMC - PubMed
    1. Dent R, Trudeau M, Pritchard K, Hanna W, Kahn H, Sawka C, Lickley L, Rawlinson E, Sun P, Narod S. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429–4434. - PubMed
    1. Dinçsoy A, Cansaran Duman D. Changes in apoptosis-related gene expression profiles in cancer cell lines exposed to usnic acid lichen secondary metabolite. Turk J Biol. 2017;41:484–493.